High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis
Background: This study explores the association of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) ratios with the 3-month treatment response and persistence of tumor necrosis factor-alpha (TNF-α) blockers in patients with ankylosing spondylitis (AS). M...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/3/379 |
| _version_ | 1827748160919830528 |
|---|---|
| author | Dong-Hyuk Moon Aran Kim Byung-Wook Song Yun-Kyung Kim Geun-Tae Kim Eun-Young Ahn Min-Wook So Seung-Geun Lee |
| author_facet | Dong-Hyuk Moon Aran Kim Byung-Wook Song Yun-Kyung Kim Geun-Tae Kim Eun-Young Ahn Min-Wook So Seung-Geun Lee |
| author_sort | Dong-Hyuk Moon |
| collection | DOAJ |
| description | Background: This study explores the association of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) ratios with the 3-month treatment response and persistence of tumor necrosis factor-alpha (TNF-α) blockers in patients with ankylosing spondylitis (AS). Methods: This retrospective cohort study investigated 279 AS patients who were newly initiated on TNF-α blockers between April 2004 and October 2019 and 171 sex- and age-matched healthy controls. Response to TNF-α blockers was defined as a reduction in the Bath AS Disease Activity Index of ≥50% or 20 mm, and persistence referred to the time interval from the initiation to discontinuation of TNF-α blockers. Results: Patients with AS had significantly increased NLR, MLR, and PLR ratios as compared to controls. The frequency of non-response at 3 months was 3.7%, and TNF-α blockers’ discontinuation occurred in 113 (40.5%) patients during the follow-up period. A high baseline NLR but not high baseline MLR and PLR showed an independently significant association with a higher risk of non-response at 3 months (OR = 12.3, <i>p</i> = 0.025) and non-persistence with TNF-α blockers (HR = 1.66, <i>p</i> = 0.01). Conclusions: NLR may be a potential marker for predicting the clinical response and persistence of TNF-α blockers in AS patients. |
| first_indexed | 2024-03-11T06:03:23Z |
| format | Article |
| id | doaj.art-91de3f23929d4ccb9ccb6d7c88849cc0 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-11T06:03:23Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-91de3f23929d4ccb9ccb6d7c88849cc02023-11-17T13:11:59ZengMDPI AGPharmaceuticals1424-82472023-03-0116337910.3390/ph16030379High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing SpondylitisDong-Hyuk Moon0Aran Kim1Byung-Wook Song2Yun-Kyung Kim3Geun-Tae Kim4Eun-Young Ahn5Min-Wook So6Seung-Geun Lee7Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, College of Medicine, Kosin University, Busan 49104, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, College of Medicine, Kosin University, Busan 49104, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University, Yangsan 50612, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University, Yangsan 50612, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of KoreaBackground: This study explores the association of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) ratios with the 3-month treatment response and persistence of tumor necrosis factor-alpha (TNF-α) blockers in patients with ankylosing spondylitis (AS). Methods: This retrospective cohort study investigated 279 AS patients who were newly initiated on TNF-α blockers between April 2004 and October 2019 and 171 sex- and age-matched healthy controls. Response to TNF-α blockers was defined as a reduction in the Bath AS Disease Activity Index of ≥50% or 20 mm, and persistence referred to the time interval from the initiation to discontinuation of TNF-α blockers. Results: Patients with AS had significantly increased NLR, MLR, and PLR ratios as compared to controls. The frequency of non-response at 3 months was 3.7%, and TNF-α blockers’ discontinuation occurred in 113 (40.5%) patients during the follow-up period. A high baseline NLR but not high baseline MLR and PLR showed an independently significant association with a higher risk of non-response at 3 months (OR = 12.3, <i>p</i> = 0.025) and non-persistence with TNF-α blockers (HR = 1.66, <i>p</i> = 0.01). Conclusions: NLR may be a potential marker for predicting the clinical response and persistence of TNF-α blockers in AS patients.https://www.mdpi.com/1424-8247/16/3/379ankylosing spondylitis (AS)tumor necrosis factor-alpha (TNF-α)treatment outcomeblood cellsbiomarkers |
| spellingShingle | Dong-Hyuk Moon Aran Kim Byung-Wook Song Yun-Kyung Kim Geun-Tae Kim Eun-Young Ahn Min-Wook So Seung-Geun Lee High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis Pharmaceuticals ankylosing spondylitis (AS) tumor necrosis factor-alpha (TNF-α) treatment outcome blood cells biomarkers |
| title | High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
| title_full | High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
| title_fullStr | High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
| title_full_unstemmed | High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
| title_short | High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
| title_sort | high baseline neutrophil to lymphocyte ratio could serve as a biomarker for tumor necrosis factor alpha blockers and their discontinuation in patients with ankylosing spondylitis |
| topic | ankylosing spondylitis (AS) tumor necrosis factor-alpha (TNF-α) treatment outcome blood cells biomarkers |
| url | https://www.mdpi.com/1424-8247/16/3/379 |
| work_keys_str_mv | AT donghyukmoon highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT arankim highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT byungwooksong highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT yunkyungkim highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT geuntaekim highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT eunyoungahn highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT minwookso highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT seunggeunlee highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis |